melatonin has been researched along with plx4032 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Deng, W; Diao, C; Fan, W; Guo, P; Guo, W; Hao, J; Hu, S; Jiang, K; Li, L; Li, Y; Long, Q; Qin, G; Qin, L; Ren, Y; Tang, R; Tian, C; Wang, J; Yang, Q; Yu, W; Zhang, C; Zhang, X; Zhou, P; Zhu, T; Zou, L | 1 |
1 other study(ies) available for melatonin and plx4032
| Article | Year |
|---|---|
Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Male; Melanoma; Melatonin; Mice; Mice, Nude; Neoplastic Stem Cells; NF-kappa B; Nitric Oxide Synthase Type II; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Telomerase; Vemurafenib; Xenograft Model Antitumor Assays | 2019 |